One year follow up for case series of myocarditis following mRNA vaccination against SARS-CoV-2

In 2021, the first rounds of modified mRNA vaccines against SARS-CoV-2 were tested and deployed. The vaccines themselves had great efficacy against severe infection, with rare and minimal side effects. One adverse effect that was reported, however, was incidence of myocarditis seen amongst mostly young males after their second vaccination dose. The disease course was self-limited. This study group published a case series in August of 2021 of four cases of this phenomenon. This paper is a followup to the original case series, providing an updated literature review and expert recommendations concerning the safety and benefits of the vaccines. •Case series of 4 patients with SARS-CoV-2 vaccine-associated myocarditis, in whom, on follow up, had complete symptomatic and biomarker recovery.•Multiple case series suggest a epidimiology feature of mostly young males affected by SARS-CoV-2 vaccine- associated myocarditis.•Most cases were self resolving in course, without any known lasting physiological or structural cardiovascular effects.•In review of totality of the evidence reviewed of this phenomina, evidence still supports vaccination in a risk/benefit analysis.